X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, SERB has acquired exclusive US rights to the ticagrelor reversal agent PB2452 (bentracimab), a novel, monoclonal antibody fragment, from SFJ. SFJ will remain responsible for the ongoing trials of bentracimab and will work with SERB to submit the BLA.
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Serb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 11, 2023
Details:
PB2452 (bentracimab) is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: PhaseBio Pharmaceuticals
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2023
Details:
In the study, EMPAVELI met the primary endpoint, demonstrating superiority to Soliris for the change from baseline in hemoglobin level at Week 16 with an adjusted mean increase of 3.84 g/dL of hemoglobin.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Hematology Product Name: Empaveli
Highest Development Status: Phase IVProduct Type: Peptide
Recipient: Apellis Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2021
Details:
The collaboration between SFJ and Nektar will support a new Phase 2/3 registrational clinical study of BEMPEG plus pembrolizumab in patients with head and neck cancer whose tumors express PD-L1 (Combined Positive Score).
Lead Product(s): Bempegaldesleukin,Pembrolizumab
Therapeutic Area: Oncology Product Name: NKTR-214
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Nektar Therapeutics
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 17, 2021
Details:
The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.
Lead Product(s): PB2452
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: PhaseBio Pharmaceuticals
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
